Skip to main content

Table 4 OABSS and Risk of dyskinesia, Stratified by Various Baseline Characteristics

From: Unraveling the interplay between dyskinesia and overactive bladder symptoms in Parkinson’s disease: a comprehensive cohort study based on the long-term follow-up database of Parkinson’s disease

 

OABSS Interval

p for interaction

≤2

3—5

6—15

Age > Median age (64)

0.545

Yes ( n = 628)

Events/participants

22/205

15/177

127/246

OR (95% CI)

ref

0.770(0.380,1.524)ns

8.877(5.436,15.077)***

No ( n = 710)

Events/participants

29/322

11/163

94/225

OR (95% CI)

ref

0.731(0.341,1.464)ns

7.250(4.609,11.701)***

Gender = male

0.872

Yes ( n = 788)

Events/participants

34/331

11/190

126/267

OR (95% CI)

ref

0.537(0.254,1.054)ns

7.806(5.138,12.131)***

No ( n = 550)

Events/participants

17/196

15/150

95/204

OR (95% CI)

ref

1.170(0.558,2.430)ns

9.177(5.320,16.680)***

LEDD > Median LEDD (337.5)

0.134

Yes ( n = 664)

Events/participants

39/215

15/164

161/285

OR (95% CI)

ref

0.454(0.234,0.840)*

5.859(3.888,8.994)***

No ( n = 674)

Events/participants

12/312

11/176

60/186

OR (95% CI)

ref

1.667(0.709,3.884)ns

11.905(6.404,23.932)***

Duration > Median Duration (36)

0.715

Yes ( n = 634)

Events/participants

35/201

15/147

166/286

OR (95% CI)

ref

1.171(0.518,2.556) ns

8.197(4.63,15.273) ***

No ( n = 704)

Events/participants

16/326

11/193

55/185

OR (95% CI)

ref

0.539(0.275,1.011) ns

6.561(4.294,10.241) ***

NMSQ > Median NMSQ (6)

0.069

Yes ( n = 590)

Events/participants

8/73

9/169

178/348

OR (95% CI)

ref

1.055(0.570,1.874) ns

5.137(3.162,8.373) ***

No ( n = 748)

Events/participants

43/454

17/171

43/123

OR (95% CI)

ref

0.457(0.168,1.266) ns

8.507(4.192,19.698) ***

  1. Abbreviations: OABSS Over-Active Bladder Syndrome Score, LEDD Levodopa equivalent daily dose, NMSQ None Motor Symptom Questionnaire, ref reference, ns not significant; *p < 0.05, ***p < 0.001
Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us